169 related articles for article (PubMed ID: 19954980)
1. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
[TBL] [Abstract][Full Text] [Related]
2. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS
Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204
[TBL] [Abstract][Full Text] [Related]
3. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
[TBL] [Abstract][Full Text] [Related]
4. Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice.
Davison HR; Taylor S; Drake C; Phuan PW; Derichs N; Yao C; Jones EF; Sutcliffe J; Verkman AS; Kurth MJ
Bioconjug Chem; 2011 Dec; 22(12):2593-9. PubMed ID: 22034937
[TBL] [Abstract][Full Text] [Related]
5. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS
J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463
[TBL] [Abstract][Full Text] [Related]
7. Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.
Ye L; Knapp JM; Sangwung P; Fettinger JC; Verkman AS; Kurth MJ
J Med Chem; 2010 May; 53(9):3772-81. PubMed ID: 20373765
[TBL] [Abstract][Full Text] [Related]
8. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein.
Knapp JM; Wood AB; Phuan PW; Lodewyk MW; Tantillo DJ; Verkman AS; Kurth MJ
J Med Chem; 2012 Feb; 55(3):1242-51. PubMed ID: 22214395
[TBL] [Abstract][Full Text] [Related]
11. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
12. Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators.
Caldwell RA; Grove DE; Houck SA; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2011 Sep; 301(3):L346-52. PubMed ID: 21642448
[TBL] [Abstract][Full Text] [Related]
13. Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.
Donald MB; Rodriguez KX; Shay H; Phuan PW; Verkman AS; Kurth MJ
Bioorg Med Chem; 2012 Sep; 20(17):5247-53. PubMed ID: 22841006
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
Kym PR; Wang X; Pizzonero M; Van der Plas SE
Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
[TBL] [Abstract][Full Text] [Related]
16. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Verkman AS; Lukacs GL; Galietta LJ
Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
[TBL] [Abstract][Full Text] [Related]
18. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
19. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
Wang Y; Bartlett MC; Loo TW; Clarke DM
Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
